Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Liraglutide

Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus

Novo Nordisk · Phase 2 · Completed · Enrollment 957

NCT02453711

EudraCT 2014-001540-38

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

X axis: threshold category. Y axis: participants reaching threshold, %.

53.567.4974.9180.5282.5266.12
≥5%
18.9436.5755.9557.7664.6133.98
≥10%
≥15%
≥20%
  • Placebo Sema 0.05 mg
  • Placebo Sema 0.1 mg
  • Placebo Sema 0.2 mg
  • Placebo Sema 0.3 mg (fast dose escalation)
  • Placebo Sema 0.4 mg (fast dose escalation)
  • Placebo Lira 3.0 mg
Show as table
Arm≥5%≥10%≥15%≥20%
Sema 0.05 mgn/rn/rn/rn/r
Sema 0.1 mgn/rn/rn/rn/r
Sema 0.2 mgn/rn/rn/rn/r
Sema 0.3 mgn/rn/rn/rn/r
Sema 0.4 mgn/rn/rn/rn/r
Sema 0.3 mg (fast dose escalation)n/rn/rn/rn/r
Sema 0.4 mg (fast dose escalation)n/rn/rn/rn/r
Lira 3.0 mgn/rn/rn/rn/r
Placebo Sema 0.05 mg53.5%18.94%n/rn/r
Placebo Sema 0.1 mg67.49%36.57%n/rn/r
Placebo Sema 0.2 mg74.91%55.95%n/rn/r
Placebo Sema 0.3 mgn/rn/rn/rn/r
Placebo Sema 0.4 mgn/rn/rn/rn/r
Placebo Sema 0.3 mg (fast dose escalation)80.52%57.76%n/rn/r
Placebo Sema 0.4 mg (fast dose escalation)82.52%64.61%n/rn/r
Placebo Lira 3.0 mg66.12%33.98%n/rn/r

Not shown

  • Sema 0.05 mg: endpoint not reported
  • Sema 0.1 mg: endpoint not reported
  • Sema 0.2 mg: endpoint not reported
  • Sema 0.3 mg: endpoint not reported
  • Sema 0.4 mg: endpoint not reported
  • Sema 0.3 mg (fast dose escalation): endpoint not reported
  • Sema 0.4 mg (fast dose escalation): endpoint not reported
  • Lira 3.0 mg: endpoint not reported
  • Placebo Sema 0.3 mg: endpoint not reported
  • Placebo Sema 0.4 mg: endpoint not reported